ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Share :
Published: 25 Mar 2024
Views: 3703
Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini

Dr Anna Minchom (The Royal Marsden Hospital, London, UK), Prof Enriqueta Felip (Vall d'Hebron University Hospital, Barcelona, Spain), Prof Nicolas Girard (Institut Curie, Paris, France) and Prof Pascale Tomasini (Aix-Marseille University, Marseille, France) discuss the latest updates in EGFR mutant lung cancer with a focus on exon 20 mutation.

They start by discussing the latest updates from the PAPILLON trial at ELCC 2024. Then they move on to talk about the results of the phase 1b PALOMA study, which evaluated the efficacy of subcutaneous amivantamab in patients with advanced solid malignancies.

They also discuss the phase II study of becotarug in combination with osimertinib, which was conducted in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that harboured EGFR Exon 20 Insertion mutations. Finally, the panel talks about the MARIPOSA, MARIPOSA 2, and FLAURA2 studies presented at ELCC 2024.

This programme is supported by an unrestricted educational grant from Janssen.